[Pharm-policy] Mouse Genomics and Genetics and compulsory licensing

[James Love]

This is from the National Cancer Institute page on advisory boards and
groups.  This working group asks for the government to step in and set
limits on "reach-through" royalty clauses, and then basically endorses a
compulsory licensing approach.  Also singled out are the Dupont
'oncomouse' patents and the DNX Transgenic Mouse patent. Jamie


http://deainfo.nci.nih.gov/advisory/pog/directors/preclin_model/genomic_rec.htm

27sep95 Lorrie Smith revised: 31jan00

Preclinical Models for Human Cancers Working Group

         Mouse Genomics and Genetics Subgroup
                    Recommendations

 JOINT RECOMMENDATIONS: Mouse Genomics and Genetics Subgroup and
 Mouse Models of Human Cancers Subgroup 

 #1. In concert with the NIH at large, develop and implement
political initiatives that set limits on reach-through royalty
clauses on technology  transfer agreements proffered by the
holders of intellectual property, whether  in academia or
industry. Establish fair and just standards that appropriately
reward the developers of new technology, while at the same time
providing  incentive for such tools to be used widely in
biomedical research and in the  development of new therapeutics. 

     i. Develop a solution to the restrictive Dupont patents for
the 'oncomouse' and for the cre/lox technology. 

     ii. Investigate the 'Transgenic Mouse Patent' owned by DNX,
which is being aggressively protected, to the extent that smaller
biotech companies are stopping the development of transgenic
mouse models. 

     iii. Establish a national standard (and intellectual
principles) for compensation associated with the transfer of
tools and technologies, including those associated with mouse
models, as contrasted to discoveries of specific product
candidates that need broad protection to justify their
development. 



-- 
James Love, Consumer Project on Technology
v. 1.202.387.8030, fax 1.202.234.5176
love@cptech.org, http://www.cptech.org